Preclinical and clinical results with pomalidomide in the treatment of relapsed/refractory multiple myeloma Review uri icon

Overview

MeSH Major

  • Angiogenesis Inhibitors
  • Multiple Myeloma
  • Thalidomide

abstract

  • Despite the evolution of effective frontline treatment strategies, many patients with myeloma inevitably relapse. Treatment can be complicated by the interplay of disease-, treatment-, and patient-related factors. Unfortunately, many patients eventually develop disease that is refractory to lenalidomide and bortezomib and have few treatment options. Pomalidomide is a distinct IMiD agent recently approved in the US and Europe. We review the pomalidomide mechanism of action, summarizing its direct antimyeloma, immunomodulatory, and stromal-support inhibitory activities. We also detail its clinical development, including establishment of the approved dose/schedule, phase 2 and 3 trials in relapsed and refractory patients, and novel pomalidomide-based combinations.

publication date

  • January 2014

Research

keywords

  • Review

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.leukres.2014.02.008

PubMed ID

  • 24690110

Additional Document Info

start page

  • 517

end page

  • 24

volume

  • 38

number

  • 5